Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mehmet Esat Demirhan"'
Autor:
Shubham Pant, Funda Meric-Bernstam, Vivek Subbiah, Kenna M. Shaw, Kenneth R. Hess, Xiaofeng Zheng, Kavitha Balaji, Jaffer A. Ajani, Mark J. Routbort, Scott Kopetz, Mariela Blum-Murphy, Kanwal Pratap Singh Raghav, Russell Broaddus, Mehmet Esat Demirhan, Milind Javle, David S. Hong, Apostolia Maria Tsimberidou, Jordi Rodon, Sarina Anne Piha-Paul, Ecaterina Ileana Dumbrava
Publikováno v:
JCO Precision Oncology. :1-12
PURPOSE Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast and gastric and gastroesophageal junction cancers. However, less is known about the prevalence of ERBB2 ( HER2) amplification and the efficacy of HER
Autor:
Kenna R. Mills Shaw, Debu Tripathy, Senthil Damodaran, Funda Meric-Bernstam, Mehmet Esat Demirhan, Aysegul A. Sahin, Filip Janku, Xiaofeng Zheng, Agda Karina Eterovic, Lauren Brusco, Tae-Beom Kim, Ken Chen, Maryam Shariati, John Mendelsohn, Reva K. Basho, Gordon B. Mills, Jordi Rodon, Naoto T. Ueno, Russell Broaddus, Chetna Wathoo, Coya Tapia
Publikováno v:
JCO Precision Oncology. :1-15
Purpose To determine the significant genomic alterations in patients with metastatic breast cancer (MBC) and survival outcomes in common genotypes. Patients and Methods High-depth next-generation sequencing was performed for 202 genes in tumor and no
Autor:
Funda Meric-Bernstam, Alshad S. Lalani, Irmina Diala, Xiaofeng Zheng, Turcin Saridogan, Christian X. Cruz Pico, Bryce Kirby, Mehmet Esat Demirhan, Sarina Anne Piha-Paul, Scott Kopetz, Kurt W. Evans, Ming Zhao, Anil Korkut, Heping Wang, Stephen Scott, Erkan Yuca
Publikováno v:
Clin Cancer Res
Purpose: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA approved for HER2-overexpressing/amplified (HER2+) breast cancer. In this preclinical study, we explored the efficacy of neratinib in combination with inhibitors of
Publikováno v:
Phase I Oncology Drug Development ISBN: 9783030476816
It is not infrequent that patients with different cancers are affected by bodily organ dysfunction. Factors such as comorbidities, prior anticancer therapies and tumor-related issues are frequent causes of organ impairment. Since patients with bodily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09cd34b4b99e8b8619345c53216f7b77
https://doi.org/10.1007/978-3-030-47682-3_18
https://doi.org/10.1007/978-3-030-47682-3_18
Autor:
Funda Meric-Bernstam, Dong Yang, Kenna R. Mills Shaw, Richard B. Lanman, Ahmed Kaseb, Vivek Subbiah, Victoria M. Raymond, Michael P. Kahle, Mehmet Esat Demirhan, Cathy Eng, Kavitha Balaji, Nora S. Sanchez, Filip Janku, Ann Marie Bailey, Milind Javle, Chetna Wathoo
Publikováno v:
JCO Precis Oncol
PURPOSE Cell-free DNA (cfDNA) next-generation sequencing is a noninvasive approach for genomic testing. We report the frequency of identifying alterations and their clinical actionability in patients with advanced/metastatic cancer. PATIENTS AND METH
Autor:
Monica Loghin, Rebecca Harrison, Kristin Alfaro-Munoz, Franco DeMonte, Jennifer L. Johnson, Krishna P. Bhat, Michael Youssef, Lily Pham, Shaan M. Raza, John de Groot, Sujit S. Prabhu, Carlos Kamiya-Matsuoka, Debra Nana Yeboa, Mehmet Esat Demirhan
Publikováno v:
Neuro Oncol
BACKGROUND Selection of systemic therapy for recurrent meningiomas with progression after resection and/or radiation therapy represents a challenge. The combination of everolimus, an mTOR inhibitor, plus octreotide long-acting repeatable (LAR), a som
Autor:
Bryce Kirby, Scott Kopetz, Erkan Yuca, Kurt W. Evans, Ming Zhao, Turcin Saridogan, Sarina Anne Piha-Paul, Funda Meric-Bernstam, Irmina Diala, Stephen Scott, Mehmet Esat Demirhan, Alshad S. Lalani
Publikováno v:
Molecular Cancer Therapeutics. 18:B003-B003
Activation of HER2 signaling by amplification or overexpression of ERBB2 (HER2) is associated with the development and progression of breast cancer. Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor which selectively inhibits EGFR, HER2
Autor:
Milind Javle, Mehmet Esat Demirhan, Kenna Rael Shaw, Ann Marie Bailey, Victoria M. Raymond, Richard B. Lanman, Cathy Eng, Kavitha Balaji, Michael P. Kahle, Dong Yang, Vivek Subbiah, Nora S. Sanchez, Funda Meric-Bernstam, Ahmed Kaseb, Chetna Wathoo, Filip Janku
Publikováno v:
Journal of Clinical Oncology. 36:12110-12110
12110Background: Cell-free DNA (cfDNA) next-generation sequencing has become a more accessible, non-invasive approach for genomic testing. We report alteration identification frequency and clinical...